No.3 Issue20
No.3 Issue20
- 2024년 11월호
- 해외여행 시 HIV/AIDS 예방
- 마버그열 유행 대비/대응
- 2024년 10월호
- 2024년 9월호
- 오로푸치열 확산, 검사의뢰 안내
- 엠폭스 의심환자 신고안내
- 코로나19 치료제 수급 안정화
- 2024년 8월호
- 2024년 7월호
- 2024년 6월호
- No.8 Issue 12
- 마이코플라스마 폐렴 유행 증가
- No.8 Issue 11
- No.8 Issue 10
- No.8 Issue 09
- No.8 Issue 08
- No.8 Issue 07
- No.8 Issue 06
- No.8 Issue 05
- No.8 Issue 04
- No.8 Issue 03
- No.8 Issue 02
- No.8 Issue 01
- No.7 Issue 09
- No.7 Issue 08
- No.7 Issue 07
- No.7 Issue 06
- No.7 Issue 05
- No.7 Issue 04
- 원숭이두창, 첫 사례 발생
- No.7 Issue 03
- 원숭이 두창(Monkeypox virus)
- No.7 Issue 02
- No.7 Issue 01
- No.6 Issue 24
- No.6 Issue 23
- No.6 Issue 22
- No.6 Issue 21
- No.6 Issue 20
- No.6 Issue 19
- No.6 Issue 18
- No.6 Issue 17
- No.6 Issue 16
- No.6 Issue 15
- No.6 Issue 14
- No.6 Issue 13
- No.6 Issue 12
- 혈소판감소성 혈전증(TTS)
- No.6 Issue 11
- No.6 Issue 10
- No.6 Issue 09
- No.6 Issue 08
- No.6 Issue 07
- No.6 Issue 06
- No.6 Issue 05
- No.6 Issue 04
- No.6 Issue 03
- No.6 Issue 02
- No.6 Issue 01
- No.5 Issue 25
- No.5 Issue 24
- No.5 Issue 23
- No.5 Issue 22
- No.5 Issue 21
- No.5 Issue 20
- No.5 Issue 19
- No.5 Issue 18
- No.5 Issue 17
- No.5 Issue 16
- No.5 Issue 15
- No.5 Issue 14
- No.5 Issue 13
- No.5 Issue 12
- No.5 Issue 11
- No.5 Issue 10
- No.5 Issue 09
- 코로나바이러스감염증-19
- No.5 Issue 08
- No.5 Issue 07
- No.5 Issue 06
- No.5 Issue 05
- No.5 Issue 04
- No.5 Issue 03
- No.5 Issue 02
- 신종 코로나바이러스 감염증
- 신종 코로나바이러스
- No.5 Issue 01
- 중국 폐렴
- No.4 Issue 23
- No.4 Issue 22
- No.4 Issue 21
- No.4 Issue 20
- No.4 Issue 19
- No.4 Issue 18
- No.4 Issue 17
- 전자담배(액상형)
- A형간염
- No.4 Issue 16
- No.4 Issue 15
- No.4 Issue 14
- No.4 Issue 13
- No.4 Issue 12
- No.4 Issue 11
- No.4 Issue 10
- No.4 Issue 9
- No.4 Issue 8
- No.4 Issue 7
- No.4 Issue 6_
- No.4 Issue 5
- No.4 Issue 4
- No.4 Issue 3
- No.4 Issue2
- 홍역
- No.4 Issue1
- No.3 Issue26
- No.3 Issue25
- No.3 Issue24
- No.3 Issue23
- 인플루엔자
- No.3 Issue22
- No.3 Issue21
- No.3 Issue20
- No.3 Issue19
- 메르스
- 메르스
- No.3 Issue18
- No.3 Issue17
- No.3 Issue16
- No.3 Issue15
- No.3 Issue14
- No.3 Issue13
- No.3 Issue12
- No.3 Issue11
- 홍역
- No.3 Issue10
- No.3 Issue9
- No.3 Issue8
- No.3 Issue7
- No.3 Issue6
- No.3 Issue5
- No.3 Issue4
- No.3 Issue3
- No.3 Issue2
- No.3 Issue1
- No.2 Issue24
- No.2 Issue23
- 계절인플루엔자
- No.2 Issue22
- No.2 Issue21
- No.2 Issue20
- No.2 Issue19
- No.2 Issue18
- No.2 Issue17
- No.2 Issue16
- No.2 Issue15
- No.2 Issue14
- No.2 Issue13
- No.2 Issue12
- No.2 Issue11
- 감염병뉴스속보 [메르스]
- No.2 Issue10
- No.2 Issue9
- No.2 Issue8
- No.2 Issue7
- No.2 Issue6
- No.2 Issue5
- No.2 Issue4
- No.2 Issue3
E-NEWS LETTER 2024.06.14
X
귀하의 선택은 오답입니다.
-
1. 독시사이클린
0%
-
2. 아지스로마이신 (정답)
0%
-
3. 페니실린
0%
-
4. 세프트리악손 (선택)
0%
-
5. 세파클러
0%
참여수:0명
정답 2.
환자의 피부병변은 쯔쯔가무시병에서 전형적으로 보이는 가피(eschar)이다. 쯔쯔가무시에서 가피는 진단을 내릴 수 있는 병변에 해당한다. 이 환자는 임산부로서 쯔쯔가무시의 주치료제인 독시사이클린을 사용할 없으므로 아지스로마이신으로 치료해야한다.
쯔쯔가무시 감염병 정보
질병관리본부 감염병포털 (http://www.cdc.go.kr/npt/biz/npp/portal/nppSumryMain.do)
본 내용은 질병관리청(